Skip to content, or skip to search.

Skip to content, or skip to search.

Electroboy's Latest Shocker

Big pharma tell-all.


After publishing Electroboy, a 2002 account of his electroshock therapy to treat bipolar disorder, Andy Behrman spent a couple years flacking Abilify for Bristol-Myers Squibb to doctors and drug reps. Originally a schizophrenia drug, it was often prescribed “off label” for bipolar patients like him. And now he’s about to shop a tell-all called Adventures in the Drug Trade: I Was a Big Pharma Pusher. “To have a behind-the-scenes look at their marketing techniques was more shocking than anything I’ve ever experienced,” he says. In 2007, the company doled out over $515 million to settle a civil suit alleging that it had illegally marketed Abilify to pediatric and elderly patients and paid doctors “illegal remuneration.” In the first nine months of 2008, Abilify’s U.S. sales were $1.186 billion. A Bristol-Myers Squibb spokeswoman says its internal review of Behrman’s claims “concluded that our conduct was appropriate and within compliance of the law.”

Have good intel? Send tips to


Current Issue
Subscribe to New York

Give a Gift